The FDA has granted a priority review designation to a biologics license application for SL-401 (tagraxofusp, Elzonris) for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm.
Original Article: FDA Grants SL-401 Priority Review for Rare Hematologic Cancer